Ultragenyx Pharmaceutical Company Profile (NASDAQ:RARE)

Analyst Ratings

Consensus Ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) (?)
Ratings Breakdown: 2 Hold Rating(s), 15 Buy Rating(s)
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $96.27 (79.17% upside)

Analysts' Ratings History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Show:
DateFirmActionRatingPrice TargetActions
7/18/2016Robert W. BairdReiterated RatingOutperform$85.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/17/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/17/2016Piper Jaffray Cos.Reiterated RatingOverweight$70.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/15/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/15/2016Leerink SwannReiterated RatingBuy$85.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/15/2016Canaccord GenuityReiterated RatingBuy$120.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016Credit Suisse Group AGReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/28/2016WedbushReiterated RatingOutperform$92.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/28/2016Bank of America Corp.Initiated CoverageBuy$72.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016Morgan StanleyReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016JMP SecuritiesReiterated RatingBuy$80.00 -> $84.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$125.00 -> $85.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/28/2016HC WainwrightReiterated RatingBuy$104.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/19/2016Citigroup Inc.Lower Price Target$88.00 -> $67.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/9/2016Sterne Agee CRTInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/1/2015Stifel NicolausInitiated CoverageBuy -> Buy$125.00 -> $125.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/31/2015Raymond James Financial Inc.Initiated CoverageOutperform$125.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/13/2015SunTrust Banks Inc.Boost Price TargetBuy$82.00 -> $119.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/30/2015MLV & Co.Initiated CoverageBuy$79.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/24/2015CRT CapitalInitiated CoverageBuy$90.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/9/2016Q1($1.29)($1.35)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q4($1.14)($1.42)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q3($0.87)($1.03)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q215($0.63)($0.83)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q1 15($0.54)($0.63)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/25/2015Q414($0.53)($0.52)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.46)($0.50)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014Q214($0.42)($0.45)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q114($0.37)($0.85)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/24/2014($0.38)($4.98)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($1.38)($1.13)($1.26)
Q2 20164($1.59)($1.13)($1.39)
Q3 20164($1.75)($1.26)($1.50)
Q4 20164($1.92)($1.40)($1.61)
Q1 20171($1.70)($1.70)($1.70)
Q2 20171($1.78)($1.78)($1.78)
Q3 20171($1.87)($1.87)($1.87)
Q4 20171($1.95)($1.95)($1.95)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/21/2016Sunil AgarwalInsiderSell649$52.68$34,189.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2016Emil D KakkisCEOSell20,000$50.85$1,017,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/20/2016Sunil AgarwalInsiderSell650$54.16$35,204.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/24/2016Sunil AgarwalInsiderSell650$66.00$42,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2016Emil D KakkisCEOSell20,000$59.95$1,199,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/20/2016Sunil AgarwalInsiderSell649$70.53$45,773.97View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2016Emil D KakkisCEOSell20,000$70.33$1,406,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/22/2016Sunil AgarwalInsiderSell650$61.45$39,942.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/22/2016Sunil AgarwalInsiderSell658$63.48$41,769.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2016Sunil AgarwalinsiderSell585$72.83$42,605.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/31/2015Emil D. KakkisCEOSell20,000$114.52$2,290,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/22/2015Sunil AgarwalInsiderSell498$114.81$57,175.38View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2015Theodore Alan HuizengainsiderSell1,500$110.55$165,825.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2015Sunil AgarwalinsiderSell17,020$111.18$1,892,283.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2015Thomas Richard KassbergSVPSell3,334$109.70$365,739.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015Shalini SharpCFOSell3,854$131.95$508,535.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/8/2015Thomas Richard KassbergSVPSell3,334$102.12$340,468.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2015Shalini SharpCFOSell4,000$96.08$384,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2015Theodore Alan HuizengaInsiderSell1,500$94.80$142,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2015Thomas Richard KassbergSVPSell3,334$88.19$294,025.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/20/2015Shalini SharpCFOSell4,000$62.23$248,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/8/2015Thomas Richard KassbergSVPSell3,333$58.02$193,380.66View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2015Shalini SharpCFOSell4,000$51.24$204,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2014Shalini SharpCFOSell4,000$44.82$179,280.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2014Thomas Richard KassbergSVPSell3,333$40.22$134,053.26View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2014William AliskiDirectorSell6,000$42.16$252,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2014Shalini SharpCFOSell4,000$44.07$176,280.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2014Thomas Richard KassbergSVPSell3,333$41.85$139,486.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/8/2014Thomas Richard KassbergSVPSell3,333$53.26$177,515.58View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2014Shalini SharpCFOSell4,000$56.00$224,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2014Thomas Richard KassbergSVPSell3,333$54.82$182,715.06View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2014Thomas Richard KassbergSVPSell20,000$53.91$1,078,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2014Shalini SharpCFOSell4,000$53.97$215,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/14/2014Group Holdings (Sbs) Advis TpgInsiderSell488,820$37.60$18,379,632.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/31/2014Fmr LlcInsiderBuy175,000$21.00$3,675,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/30/2014Shalini SharpCFOBuy4,500$21.00$94,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/30/2014Thomas Richard KassbergSVPBuy1,500$21.00$31,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/30/2014William AliskiDirectorBuy5,000$21.00$105,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Ultragenyx Pharmaceutical (NASDAQ:RARE)
DateHeadline
07/21/16 06:23 PMInsider Trading Activity - Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Finance Daily
07/21/16 08:55 AMUltragenyx Pharmaceutical Inc. (NASDAQ:RARE): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/21/16 08:55 AMUltragenyx Pharmaceutical Inc (RARE) Drops 5.57% on July 19 - Equities.com
07/19/16 07:01 AMHot Biotech Stocks Recap: Amicus Therapeutics, Inc. (NASDAQ:FOLD), Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - The Voice Registrar
07/18/16 11:32 AMUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Wall Street Analyst Recommendation Outlook - TGP
07/18/16 11:32 AMPerformance watch list: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - News Oracle
07/15/16 11:11 AMUltragenyx's Final Stage Study Of Recombinant Human Beta-Glucuronidase Meets Primary Endpoint
07/15/16 11:11 AMUltragenyx Pharmaceutical Inc. (RARE) Is Rising On Phase 3 Study Results
07/15/16 11:11 AMUnderstanding The Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Data Dump
07/14/16 06:16 PMEye on Stock Volatility for: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Engelwood Daily
07/14/16 06:16 PMUltragenyx Pharma (RARE) Announces rhGUS Phase 3 Met Primary Endpoint in Sly Syndrome - StreetInsider.com
07/14/16 04:11 PMULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
07/14/16 03:34 PMUltragenyx shares rise on metabolic drug study results -
07/14/16 03:18 PMUltragenyx Announces Positive Topline Data from Phase 3 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7 - [at noodls] - Study meets primary endpoint of reduction in urinary GAG excretion and provides evidence of clinical improvement Company to host conference call today at 5pm ET to discuss results NOVATO, Calif., July ...
07/14/16 09:39 AM3 Stocks to Watch on Thursday: Monsanto Company (MON), Ultragenyx Pharmaceutical Inc (RARE) and Yum! Brands ... - Investorplace.com
07/14/16 08:45 AM3 Stocks to Watch on Thursday: Monsanto Company (MON), Ultragenyx Pharmaceutical Inc (RARE) and Yum! Brands, Inc. (YUM) - InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips Yum Brands (YUM) beat second-quarter expectations, Monsanto (MON) looks to combine its agrochemical business with another company, and more. The post 3 Stocks to Watch on Thursday: Monsanto Company (MON), Ultragenyx Pharmaceutical Inc (RARE) and Yum! Brands, Inc. (YUM) appeared first on InvestorPlace.
07/13/16 06:26 PMUltragenyx Pharma (RARE) to Present Phase 3 Data for rhGUS in MPS 7 at MPS Symposium - StreetInsider.com
07/13/16 03:38 PMUltragenyx to Present Phase 3 Data for Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7 (MPS 7) at 14th International Symposium on MPS and Related Diseases - [at noodls] - NOVATO, Calif., July 13, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ...
07/13/16 03:18 PM4:18 pm Ultragenyx Pharma announces that data from the Phase 3 study of recombinant human beta-glucuronidase will be presented at the 14th International Symposium on MPS and Related Diseases, taking place July 14-17 in Bonn, Germany -
07/12/16 06:18 PMUltragenyx Pharmaceutical Inc Draws Bearish Attention After Forming Double Bottom Pattern - Consumer Eagle
07/12/16 06:18 PMNext Weeks Broker Price Targets For Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) - Fiscal Standard
07/12/16 06:18 PMAnalyst Target and Average Rating Watch: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Press Telegraph
07/12/16 06:18 PMUltragenyx Pharmaceutical Inc Realized Volatility Hits Extreme Level - CML News
07/10/16 10:05 AMLook Out For Analyst's Recommendation: Ultragenyx Pharmaceutical Inc. (RARE) - Post Registrar
07/07/16 05:42 AMCoverage initiated on Ultragenyx Pharma by Piper Jaffray -
07/06/16 06:19 PMCan Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Improve on the Earnings Front? - Engelwood Daily
07/06/16 06:19 PMShares of Ultragenyx Pharmaceutical (RARE) Sees Large Inflow of Net Money Flow - Trade Calls
07/06/16 06:19 PMUltragenyx Pharmaceutical Inc (RARE) Jumps 5.72% on July 04 - Equities.com
07/05/16 10:29 AMBank of America Initiates Coverage on Ultragenyx Pharmaceutical Inc to Buy - TheFounders Daily
07/05/16 05:12 AMULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements a -
07/03/16 10:12 AMUltragenyx Pharmaceutical Incorporated (NASDAQ:RARE) Short Interest Increased By 5.44% - Press Telegraph
07/01/16 08:49 AMHow Analysts Feel About Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)? - Engelwood Daily
06/30/16 06:18 PMNew Broker Ratings For Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) - FTSE News
06/29/16 05:58 PMUltragenyx's KRN23 a Breakthrough Therapy for rare bone disorder - Seeking Alpha
06/29/16 05:58 PMStocks Preparing To Gain Concentrations- Xencor (NASDAQ:XNCR), Ultragenyx Pharmaceutical (NASDAQ:RARE ... - Seneca Globe
06/28/16 12:55 PMStreet Talk: MSFT, SCTY, DKS, PAG & RARE -
06/28/16 10:51 AMUltragenyx Pharma Receives Breakthrough Therapy Designation For KRN23
06/28/16 07:41 AMUltragenyx Receives Breakthrough Therapy Designation for KRN23 in Pediatric Patients with X-Linked Hypophosphatemia - [at noodls] - NOVATO, Calif., June 28, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ...
06/25/16 05:28 PMStock Tracing Lower on the Week Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Engelwood Daily
06/25/16 05:28 PMPrice Target Update on Ultragenyx Pharmaceutical (NASDAQ:RARE) - Trade Calls
06/22/16 06:00 PMUltragenyx Pharmaceutical Inc (RARE) is Trading Lower on Unusual Volume for June 21 - Equities.com
06/21/16 05:35 PMLongtime Allergan Lawyer Named GC of Ultragenyx
06/21/16 05:35 PMUltragenyx Pharmaceutical : Appoints Karah Parschauer as Executive Vice President, General Counsel
06/20/16 07:30 AMUltragenyx Appoints Karah Parschauer as Executive Vice President, General Counsel - [GlobeNewswire] - NOVATO, Calif., June 20, 2016-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has appointed ...
06/17/16 02:52 PMChief Medical Officer Resignation Will Not Affect Ultragenyx's Catalyst-Rich Timeline - After Thursday's close, Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) noted in its 8-k form about CMO Sunil Agarwal's resignation. The decision is effective August 18. The reason for the move was categorized as seeking a different career path. During the imminent search process for a new chief medical officer, CEO Emil Kakkis will lead the development leadership team. Taking into consideration management's report, according to which no changes took place concerning clinical and regulatory timelines, Canaccord Genuity still predicts multiple catalysts from the company's diverse pipeline. This pipeline includes clinical data and/or regulatory decisions ...Full story available on Benzinga.com
06/17/16 08:46 AMUltragenyx, Takeda To Develop Drugs For Rare Genetic Diseases
06/16/16 06:16 PMUltragenyx Pharma (RARE) CMO to Resign - StreetInsider.com
06/16/16 03:40 PMULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Other Events -
06/15/16 03:03 PMULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/15/16 10:35 AMJMP Securities Maintains Ultragenyx Pharmaceutical Inc to Market Outperform with Price Target $84.00 - Trade Calls

Social

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical logoUltragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. Recombinant human beta-glucuronidase (rhGUS), is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7 (MPS 7). It is developing UX007 for oral administration intended as a substrate replacement therapy. It is developing aceneuramic acid extended-release (Ace-ER) for the treatment of GNE myopathy.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RARE
  • CUSIP:
Key Metrics:
  • Previous Close: $52.32
  • 50 Day Moving Average: $55.70
  • 200 Day Moving Average: $63.40
  • P/E Ratio: N/A
  • P/E Growth: -0.23
  • Market Cap: $2.10B
  • Beta: 1.32
  • Current Year EPS Consensus Estimate: $-6 EPS
  • Next Year EPS Consensus Estimate: $-6.07 EPS
Additional Links:
Ultragenyx Pharmaceutical (NASDAQ:RARE) Chart for Saturday, July, 23, 2016